GVHD Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.
Featured
Study findings showed that vedolizumab 300 mg was tolerable and led to low incidence of overall and lower-intestinal aGVHD in patients who undergo allo-HSCT.
View More
Xue-Zhong Yu, MD, MS, MBA, discusses Sirtuin-1 as a possible therapeutic target for the control of GVHD.
View More
In a phase 2 clinical trial, ruxolitinib was well-tolerated and led to responses in >50% of patients with steroid-refractory acute GVHD.
View More
Ruxolitinib significantly improved efficacy outcomes over common therapy options for patients with glucocorticoid-refractory acute GVHD after allogeneic stem cell transplantation.
View More
Oncologists may be able to reduce GVHD preventative measures for pediatric patients with acute leukemia post-HSCT.
View More
Stay in the know.
OncNet Newsletter